Overview

Echinaforce Junior Bioavailability Trial

Status:
Withdrawn
Trial end date:
2018-06-30
Target enrollment:
Participant gender:
Summary
In this bioavailability trial should be shown that the one of the main active constituent in alcoholic echinacea extracts, the alkylamide dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamide (short: tetraen) is bioavailable in children of different age groups after intake of 5 Echinaforce junior tablets.
Phase:
Phase 4
Details
Lead Sponsor:
A. Vogel AG
Bioforce AG
Collaborator:
University Children's Hospital, Zurich